发明授权
- 专利标题: KIR-binding agents and methods of use thereof
- 专利标题(中): KIR结合剂及其使用方法
-
申请号: US12244101申请日: 2008-10-02
-
公开(公告)号: US08388970B2公开(公告)日: 2013-03-05
- 发明人: Søren Berg Padkær , Peter Andreas Nicolai Reumert Wagtmann , Pieter Spee , Stefan Zahn , Kristian Kjærgaard , Anders Svensson
- 申请人: Søren Berg Padkær , Peter Andreas Nicolai Reumert Wagtmann , Pieter Spee , Stefan Zahn , Kristian Kjærgaard , Anders Svensson
- 申请人地址: DK Bagsvaerd FR Marseilles
- 专利权人: Novo Nordisk A/S,Innate Pharma S.A.S.
- 当前专利权人: Novo Nordisk A/S,Innate Pharma S.A.S.
- 当前专利权人地址: DK Bagsvaerd FR Marseilles
- 代理机构: Hunton & Williams LLP
- 优先权: DK200500021 20050106
- 主分类号: A61K39/395
- IPC分类号: A61K39/395 ; A61K39/00
摘要:
The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.
公开/授权文献
- US20090075340A1 Kir-Binding Agents and Methods of Use Thereof 公开/授权日:2009-03-19